Table 2. Box-Behnken design for preparation of CBZ NLC in-situ gel .
| Batch | X 1 a | X 2 b | X 3 c |
| F1 | -1 | 0 | -1 |
| F2 | 0 | 0 | 0 |
| F3 | -1 | 0 | 1 |
| F4 | -1 | -1 | 0 |
| F5 | 1 | 0 | -1 |
| F6 | 0 | -1 | -1 |
| F7 | 0 | 0 | 0 |
| F8 | 0 | 1 | 1 |
| F9 | 0 | 0 | 0 |
| F10 | -1 | 1 | 0 |
| F11 | 1 | 0 | 1 |
| F12 | 1 | -1 | 0 |
| F13 | 0 | -1 | 1 |
| F14 | 1 | 1 | 0 |
| F15 | 0 | 1 | -1 |
| F16 | 0 | 0 | 0 |
| F17 | 0 | 0 | 0 |
aX1= Concentration of poloxamer 188 (-1 = 0% w/w, 0 = 5%w/w, 1 = 10% w/w), bX2=Type of polymer = (-1 = hydroxy propyl methyl cellulose, 0 = hydroxyl ethyl cellulose, 1 = Chitosan), cX3= Mucoadhesive polymer concentration (-1= 0.2% w/w, 0= 0.4% w/w, 1= 0.6%w/w), CBZ: Carbamazepine, NLC: Nanostructured lipid carriers